PubRank

H Goldschmidt

Author PubWeight™ 96.95‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2011 4.47
2 Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 2001 1.68
3 Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol 2002 1.67
4 High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 2001 1.51
5 Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia 2008 1.46
6 Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2012 1.43
7 Peripherally inserted central venous catheters for autologous blood progenitor cell transplantation in patients with haematological malignancies. Support Care Cancer 2003 1.39
8 Acne fulminans: investigation of acute febrile ulcerative acne. Arch Dermatol 1977 1.39
9 A gene expression signature for high-risk multiple myeloma. Leukemia 2012 1.36
10 Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006 1.29
11 Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007 1.28
12 Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant 2005 1.27
13 Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 2006 1.21
14 Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer 2009 1.17
15 Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994 1.13
16 Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759]. BMC Cancer 2005 1.10
17 Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 2009 1.10
18 Diffuse and banded melanin pigmentation in nails. Arch Dermatol 1972 1.09
19 Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia 2002 1.09
20 Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. Br J Haematol 1999 1.06
21 Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol 2014 1.05
22 Reactions to ionizing radiation. J Am Acad Dermatol 1980 1.04
23 Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003 1.04
24 Dermatitis associated with an implanted cardiac pacemaker. Arch Dermatol 1970 1.03
25 Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia 2010 1.03
26 High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant 2004 1.00
27 Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. Int J Cancer 2001 0.99
28 High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysis. Leukemia 2003 0.99
29 Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002 0.97
30 [Trichostasis spinulosa. A frequent follicular age-dependent change of the facial skin]. Hautarzt 1975 0.93
31 Radiotherapy of skin cancer: modern indications and techniques. Cutis 1976 0.92
32 Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance. Cancer Genet Cytogenet 2006 0.92
33 Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia 1999 0.90
34 Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001 0.90
35 Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgery. Br J Cancer 2006 0.88
36 A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol 1997 0.88
37 Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004 0.87
38 Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant 2007 0.86
39 Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2009 0.86
40 Influence of index of individuality on false positives in repeated sampling from healthy individuals. Clin Chem Lab Med 2001 0.85
41 Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996 0.84
42 The index of individuality is often a misinterpreted quantity characteristic. Clin Chem Lab Med 1999 0.84
43 [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy]. Rofo 2004 0.84
44 Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma. Int J Hematol 2011 0.84
45 Bladder necrosis caused by use of THAM in a newborn infant. J Urol 1974 0.84
46 Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Med Wkly 2006 0.83
47 Angiogenesis in hematologic malignancies. Ann Hematol 2001 0.83
48 Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant 1999 0.83
49 Exfoliative cytology of human horny layer. Methods of cell removal and microscopic techniques. Arch Dermatol 1967 0.82
50 Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood 2001 0.81
51 No evidence for involvement of the promoter polymorphism -866 G/A of the UCP2 gene in childhood-onset obesity in humans. Exp Clin Endocrinol Diabetes 2003 0.81
52 Surface area measurements of psoriatic corneocytes: effects of intralesional steriod therapy. J Invest Dermatol 1979 0.81
53 Increased sebum secretion following selenium sulfide shampoos. Acta Derm Venereol 1968 0.81
54 Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haematol 1997 0.81
55 Desquamation of the human horny layer. Arch Dermatol 1967 0.81
56 No evidence for involvement of alleles of the 825-C/T polymorphism of the G-protein subunit beta 3 in body weight regulation. Exp Clin Endocrinol Diabetes 2001 0.81
57 Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol 1993 0.80
58 Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors. Br J Cancer 2013 0.80
59 [Effects of a programme for structured outpatient follow-up care after inpatient rehabilitation of obese children and adolescents--a multicentre, randomized study]. Rehabilitation (Stuttg) 2006 0.80
60 Altered self-reactive antibody repertoires are a general feature of patients with myelodysplastic syndrome. J Autoimmun 2001 0.80
61 Malignant lymphoma, reticulum cell type. Ultrastructural and cytological demonstration of Lutzner cells. Arch Dermatol 1971 0.80
62 The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery. Br J Haematol 1998 0.79
63 Dermatologic radiotherapy and thyroid cancer. Dose measurements and risk quantification. Arch Dermatol 1983 0.79
64 Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007 0.79
65 Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2001 0.79
66 Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Ann Hematol 2001 0.79
67 Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation. Clin Res Cardiol 2006 0.78
68 Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer. Eur J Cancer 1997 0.78
69 Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation. Bone Marrow Transplant 2002 0.78
70 CD19+ and CD20+ B cells from the peripheral blood of patients with multiple myeloma are not infected with human herpesvirus 8. Leukemia 2000 0.78
71 Office radiotherapy of cutaneous carcinomas. II. Indications in specific anatomic regions. J Dermatol Surg Oncol 1983 0.78
72 Dermatologic radiotherapy. The risk-benefit ratio. Arch Dermatol 1986 0.78
73 Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2001 0.78
74 Central venous catheter-related complications. Antibiot Chemother (1971) 2000 0.78
75 Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant 2006 0.78
76 Large-bore central venous catheters for the collection of peripheral blood stem cells. J Clin Apher 1995 0.77
77 High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1996 0.77
78 [Dermatologic roentgen therapy and radiocarcinogenesis]. Hautarzt 1982 0.77
79 Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer. J Cancer Res Clin Oncol 1998 0.77
80 Ceftriaxone for the treatment of febrile episodes in nonneutropenic patients with hematooncological disease or HIV infection: comparison of outpatient and inpatient care. Chemotherapy 2001 0.77
81 Contact radiotherapy of cutaneous hemangiomas: therapeutic effects and radiation sequelae in 818 patients. Arch Dermatol Res 1975 0.77
82 Continuous complete remission in adult patients with acute lymphocytic leukaemia at a median observation of 12 years after autologous bone marrow transplantation. Br J Haematol 2001 0.77
83 [Correlation of MRI and histopathology of bone marrow in patients with multiple myeloma]. Rofo 2005 0.77
84 Successful autologous peripheral blood stem cell transplantation in a Jehovah's Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products. Int J Hematol 2008 0.77
85 A rationale for positive selection of peripheral blood stem cells in multiple myeloma: highly purified CD34+ cell fractions of leukapheresis products do not contain malignant cells. Leukemia 1997 0.77
86 Transient complete remission of metastasized Merkel cell carcinoma by high-dose polychemotherapy and autologous peripheral blood stem cell transplantation. Br J Dermatol 2000 0.77
87 Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells. Blood 1995 0.77
88 Long-term survival after surgical intervention for bone disease in multiple myeloma. Ann Oncol 2005 0.77
89 Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995 0.77
90 Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. Br J Cancer 1999 0.76
91 Decreased numbers of circulating B cells in myeloma patients with reduction after conventional chemotherapy. Am J Hematol 1998 0.76
92 Radiotherapy of benign dermatoses: indications, practice, and results. J Dermatol Surg Oncol 1978 0.76
93 Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplant 2000 0.76
94 Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Ann Oncol 2005 0.76
95 Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 1998 0.76
96 Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma. Ann Oncol 2004 0.76
97 Detection of treated liver metastases using fluorine-18-fluordeoxyglucose (FDG) and positron emission tomography (PET). Anticancer Res 2000 0.76
98 Successful collection and transplantation of peripheral blood stem cells in cancer patients using large-volume leukaphereses. J Clin Apher 1996 0.76
99 Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation. Int J Antimicrob Agents 2000 0.76
100 Antiangiogenic therapy in hematologic malignancies. Curr Pharm Des 2004 0.76
101 Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma. Bone Marrow Transplant 1993 0.76
102 Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. Leukemia 2011 0.76
103 The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken. Eur Radiol 2014 0.75
104 Thalidomide in multiple myeloma. Curr Pharm Biotechnol 2006 0.75
105 [Sequelae of splenectomy]. Z Arztl Fortbild (Jena) 1986 0.75
106 Clonotypic B cells in the peripheral blood of patients with multiple myeloma. Blood 2001 0.75
107 Successful treatment of bronchiolitis obliterans organizing pneumonia with low-dose methotrexate in a patient with Hodgkin's disease. Oncology 2001 0.75
108 High-dose therapy with peripheral blood stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: long-term outcome and prognostic factors. Ann Hematol 2000 0.75
109 Characterization of peripheral blood progenitor cells mobilized by cytotoxic chemotherapy and recombinant human granulocyte colony-stimulating factor. J Hematother 1994 0.75
110 A model for setting analytical quality specifications and design of control for measurements on the ordinal scale. Clin Chem Lab Med 2000 0.75
111 Dermatologic radiotherapy 1981. Arch Dermatol 1981 0.75
112 [The basics of iron metabolism]. Dtsch Med Wochenschr 1994 0.75
113 Absence of a correlation between Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) and multiple myeloma. Blood 1998 0.75
114 Dermatologic radiotheraphy: selection of radiation qualities and treatment techniques. Int J Dermatol 1976 0.75
115 Antimicrobial therapy in neutropenic patients. Antibiot Chemother (1971) 2000 0.75
116 Herpes simplex infection complicating Darier's disease. Caused by type 1 herpesvirus hominis. Arch Dermatol 1970 0.75
117 A case of mu heavy-chain disease associated with hyperglobulinemia, anemia, and a positive Coombs test. Ann Hematol 1998 0.75
118 First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield. Bone Marrow Transplant 1998 0.75
119 FDA recommendations on ionizing radiation therapy of benign diseases. J Am Acad Dermatol 1980 0.75
120 Mohs micrographic surgery as only means of optimal patient outcome? Arch Dermatol 1987 0.75
121 Autologous blood progenitor cell transplantation in relapsed Hodgkin's disease--the role of haematopoietic growth factors. Bone Marrow Transplant 1993 0.75
122 Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis. Int J Hematol 2008 0.75
123 Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Exp Hematol 1998 0.75
124 Progressive renal failure in two breast cancer patients after high-dose ifosfamide. Lancet 1994 0.75
125 Common female alopecias, diagnosis and treatment. J Am Med Womens Assoc 1969 0.75
126 Localized acneiform eruption following cobalt irradiation. Br J Dermatol 1972 0.75
127 Recombinant human erythropoietin in the treatment of cancer. Antibiot Chemother (1971) 2000 0.75
128 Systematic screening for mutations in the human necdin gene (NDN): identification of two naturally occurring polymorphisms and association analysis in body weight regulation. Int J Obes Relat Metab Disord 2001 0.75
129 [Clincal features and treatment of multiple myeloma]. Radiologe 2014 0.75
130 [Clinical aspects of autoimmune hemolytic anemias]. Z Gesamte Inn Med 1986 0.75
131 [Ambulatory therapy of multiple myeloma with vincristine, adriamycin and dexamethasone]. Dtsch Med Wochenschr 1997 0.75
132 [Rifampicin in the retreatment of pulmonary tuberculosis]. Harefuah 1973 0.75
133 [Significance of isotope renography in the diagnosis and postoperative control of children with renal diseases]. Schweiz Rundsch Med Prax 1973 0.75
134 Dermatologic radiotherapy and breast cancer. Dose measurements and risk quantification. Arch Dermatol Res 1982 0.75
135 Immunofluorescence of Tzanck smears in pemphigus vulgaris. Acta Derm Venereol 1972 0.75
136 Exfoliative cytology of psoriasis and other common dermatoses. Quantitative analysis of parakeratotic horny cells in 266 patients. Arch Dermatol 1972 0.75
137 Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995 0.75
138 Detection of minimal residual disease by polymerase chain reaction in B cell malignancies. Stem Cells 1995 0.75
139 Green hair. Arch Dermatol 1979 0.75
140 High-dose therapy with peripheral blood stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment. Br J Haematol 1996 0.75
141 [Hemihypertrophy, nevus sebaceous, multiple bone cysts and cerebroretinal angiomatosis: a complex phakomatosis]. Helv Paediatr Acta 1977 0.75
142 [Atypical and complex phakomatoses in a 6-year-old girl]. J Genet Hum 1975 0.75
143 [Roentgen therapy of dermatoses: indications and hazards]. Hautarzt 1978 0.75
144 High-dose therapy with peripheral blood progenitor cell support in patients with non-Hodgkin's lymphoma. Stem Cells 1995 0.75
145 Quantitative analysis of skin color from melanin content of superficial skin cells. J Forensic Sci 1972 0.75
146 [Sequential high-dose therapy in patients with low-malignity non-Hodgkin's lymphoma]. Strahlenther Onkol 1995 0.75
147 [Healing and healing picture of the juvenile, solitary bone cyst]. Helv Chir Acta 1973 0.75
148 Quantification of radiation risks. J Dermatol Surg Oncol 1982 0.75
149 Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. Br J Haematol 1999 0.75
150 [Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma]. Radiologe 2000 0.75
151 [Treatment of Wilms' tumor in childhood]. Dtsch Med Wochenschr 1974 0.75
152 [Targeted therapy in the treatment of solid tumors and in hematology-oncology. Advances and disappointments]. Internist (Berl) 2006 0.75
153 Ionizing radiation therapy in dermatology. Current use in the United States and Canada. Arch Dermatol 1975 0.75
154 [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma]. Radiologe 1997 0.75
155 [Iron deficiency anemia]. Dtsch Med Wochenschr 1994 0.75
156 Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine. Bone Marrow Transplant 2002 0.75
157 Food and Drug Administration recommendations on radiation of benign diseases. Arch Dermatol 1978 0.75
158 Task force reports: dermatologic radiotherapy and thyroid cancer. Cutis 1976 0.75
159 Hematopoietic growth factors for the mobilization of peripheral blood stem cells. J Hematother 1993 0.75
160 Idiopathic hemochromatosis presenting as amenorrhea and arthritis. Am J Med 1987 0.75
161 Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1994 0.75
162 Use of erythropoietin in patients with multiple myeloma. Onkologie 2003 0.75
163 Multiple myeloma--current concepts for an interdisciplinary management. A one-day course in the continuing education program organized by the Tumor Center Heidelberg/Mannheim. 24 April 1999, Heidelberg, Germany. J Cancer Res Clin Oncol 2000 0.75
164 Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation. Int J Hematol 2013 0.75
165 [Diagnosis of Wilms' tumor]. Dtsch Med Wochenschr 1974 0.75
166 High-dose therapy and autografting with peripheral blood stem cells in malignant lymphoma: granulocyte-macrophage colony-stimulating factor for stem cell mobilization. Semin Oncol 1994 0.75
167 Office radiotherapy of cutaneous carcinomas. I. Radiation techniques, dose schedules, and radiation protection. J Dermatol Surg Oncol 1983 0.75
168 Bone marrow derived dendritic cells from patients with multiple myeloma cultured with three distinct protocols do not bear Kaposi's sarcoma associated herpesvirus DNA. Ann Oncol 1999 0.75
169 Outpatient treatment of multiple myeloma with a combination of vincristine, Adriamycin and dexamethasone. Support Care Cancer 2001 0.75
170 [Whereto and why do we rehabilitate sick children and adolescents]. Dtsch Krankenpflegez 1993 0.75
171 [Different ventilation of lungs - an indication for angiography of pulmonal-artery? (author's transl)]. Rontgenblatter 1977 0.75
172 Ceftazidime in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood stem cell support. Support Care Cancer 1999 0.75
173 Teleroentgen therapy for mycosis fungoides. J Dermatol Surg Oncol 1978 0.75
174 Treatment of chemotherapy-induced emesis. Antibiot Chemother (1971) 2000 0.75
175 [Gastrointestinal amyloidosis in IgG-kappa-light-chain plasmocytoma]. Dtsch Med Wochenschr 1995 0.75
176 Sensitivity of stromal elements from human bone marrow cells to cytosine arabinoside in vitro. Haematol Blood Transfus 1987 0.75
177 [Familial occurrence of anorectal abnormalities associated with vertebral abnormalities]. Helv Paediatr Acta 1972 0.75
178 [Acute dyspnea, subfebrile temperatures and chills in a patient with multiple myeloma]. Med Klin Intensivmed Notfmed 2013 0.75
179 Leukapheresis cells of patients with multiple myeloma collected after mobilization with chemotherapy and G-CSF do not bear Kaposi's sarcoma associated herpesvirus DNA. Br J Haematol 1998 0.75
180 [Paroxysmal nocturnal hemoglobinuria. Differentiation from other acquired hemolytic anemias and confirming the diagnosis]. Z Arztl Fortbild (Jena) 1994 0.75
181 Dermatologic radiotherapy and thyroid cancer. Arch Dermatol 1977 0.75
182 How I treat herpes simplex. Postgrad Med 1968 0.75
183 [Effect of cytosine arabinoside on the differentiation of granulocyte-monocyte progenitors (CFU-GM) and myeloid leukemia blasts (CFU-L) in vitro]. Folia Haematol Int Mag Klin Morphol Blutforsch 1988 0.75
184 Juvenile hemangioma. Arch Dermatol 1967 0.75
185 Results of radiotherapy and combined modality treatment in early stage high grade non-Hodgkin's lymphoma. Strahlenther Onkol 1994 0.75
186 [Wilms' tumor in the newborn infant. Statistics and results of follow-up studies]. Schweiz Med Wochenschr 1974 0.75
187 Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice. Int J Clin Pharmacol Ther 2010 0.75